澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation) - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

以色列 - 英文 - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 125mcg/5mcg inhaler is indicated in adults and adolescents aged 12 years and above.

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - powder for inhalation - fluticasone propionate 500 mcg - fluticasone - fluticasone - prophylactic management of all grades of asthma.fluticasone propionate is indicated for the management of copd when used in combination with long-acting bronchodilators (e.g. long-acting beta agonists (labas)).

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - powder for inhalation - fluticasone propionate 250 mcg - fluticasone - fluticasone - prophylactic management of all grades of asthma.fluticasone propionate is indicated for the management of copd when used in combination with long-acting bronchodilators (e.g. long-acting beta agonists (labas)).

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - suspension for inhalation - fluticasone propionate 250 mcg/dose - fluticasone - fluticasone - prophylactic management of all grades of asthma.fluticasone propionate is indicated for the management of copd when used in combination with long-acting bronchodilators (e.g. long-acting beta agonists (labas)).

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

momaja s.r.o - fluticasone propionate - pressurised inhalation suspension - 125 mcg/acutuation - glucocorticoids - other drugs for obstructive airway diseases, inhalants, glucocorticoids - truflo is indicated for the treatment of asthma in adults and adolescents over 16 years of age. truflo is also indicated for the treatment of severe copd in conjunction with a long-acting beta agonist (such as salmeterol) for use in adults.

亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome s.a. - fluticasone (fluticasone propionate) - suspension, pressurised inhalation - 125mcg/dose

马来西亚 - 英文 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - fluticasone propionate -